Features
By Carolyn Rogers, associate, Reddie & Grose Since their launch, Ozempic and Wegovy have dominated the headlines. Both drugs are manufactured by Danish pharmaceutical company Novo Nordisk and contain the same active ingredient, semaglutide, which is a GLP-1 receptor agonist. However, Ozempic is directed to the treatment of type 2 diabetes, whilst Wegovy is for [...]
By Dr Martin Scurr, GP and longtime Daily Mail medical columnist In an era of digital transformation, ‘connected care’ often risks becoming another jargon term. But for patients, it can mean the difference between receiving the right treatment or falling through the cracks. With four decades of clinical experience, I’ve seen firsthand how continuity of [...]
Every year, thousands of health tech startups launch with glossy pitches about revolutionsing healthcare. But few stay the course and make the long-term impact that investors and the healthcare system demand. We reached out to Health Tech World and Femtech World members who've watched the innovation cycle from every angle with the following question: What's [...]
By Sanius Health As advanced cancer therapies continue to move from research into routine care, attention is increasingly turning to how these treatments are experienced by patients in everyday life. Therapies such as CAR-T have transformed outcomes for many people with blood cancers, but they can also bring significant challenges, particularly around safety and predictability [...]
Across every area of healthcare, one truth remains constant: clinicians didn’t choose medicine to spend their days typing. Yet for many, a substantial part of the working day is consumed by documentation - a burden that has quietly grown into one of the most significant pressures in modern clinical practice. But emerging ambient speech technologies [...]
Digital health tools promise convenient access to health information and services. But many operate on a business model that depends on harvesting user data. As more and more of us turn to digital health to support our wellbeing, we asked our members: Where's the line between acceptable data use and exploitation when patients get "free" [...]
By Dr Peter Seidensticker, head of medical affairs radiology, Bayer Prostate cancer continues to be a significant global health challenge, standing as the second most prevalent cancer among men worldwide. As diagnosis and treatment evolve, it is crucial to develop strategies that effectively balance the need for early detection of aggressive, clinically relevant cancers with [...]
By Gil Bashe, managing partner, chair Global Health and Purpose, FINN Partners and HTW correspondent As investors return and IPOs loom, biotech leaders navigate the delicate balance between scientific mission and market maturity. The biotechnology sector remains one of the most dynamic frontiers in modern medicine, yet it remains one of its most financially fragile. [...]
More than 750,000 women are currently waiting for hospital gynaecology services, including routine, non-cancer referrals. In England alone, over 580,000 people are waiting for non-cancer gynaecology treatment, with almost half waiting beyond the NHS target of 18 weeks, and more than 18,000 women have been waiting for over a year. “These are not just numbers,” [...]
The NHS England Medium-Term Planning Framework 2026–2029 sets out a vision for transforming how care is delivered. With targets like treating 92 per cent of patients within 18 weeks, reducing diagnostic waits to under six weeks for 99 per cent of patients, and treating 85 per cent of cancer patients within 62 days, the Framework [...]
